Compare SkyWest Inc (SKYW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SkyWest Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? SkyWest Inc trades at $96.26 (market cap $3.69B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 36.3× SkyWest Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals.
| SKYW | VRTX | |
|---|---|---|
Market Cap | $3.69B | $134.06B |
Sector | Technology | Health |
52-Week High | $115.94 | $557.96 |
52-Week Low | $78.40 | $376.62 |
Enterprise Value | $5.47B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SkyWest (SKYW) trades at $94.98, down 4.12% on the day, amid a bearish technical signal. The stock shows mixed earnings performance with a recent Q2 2026 miss but a Q1 beat, while maintaining solid profitability with a net margin of 9.78% and ROE of 15.34%. Valuation metrics appear attractive with a P/E of 9.44 and P/S of 0.92, below industry averages. Recent news highlights institutional interest and fleet expansion as growth drivers.
The outlook is cautiously optimistic given strong analyst support—56% buy ratings with a $112 consensus target—and robust cash flow trends. Key risks include earnings volatility, cost pressures from maintenance and fuel, and insider selling. The stock presents a value opportunity if operational execution improves, but investors should monitor quarterly results for sustained momentum.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
